You are viewing the site in preview mode
Skip to main content
|
Data source
|
OS curve
|
Proportion in OS (%)
|
Median OS, month
|
Mean OS, month
|
|---|
|
6 months
|
1 year
|
2 years
|
3 years
|
4 years
|
5 years
|
10 years
|
15 years
|
20 years
|
25 years
|
|---|
|
Dependent 1-knot spline normal (base-case analysis)
|
NIVO
|
89.9
|
75.0
|
53.0
|
38.5
|
29.0
|
22.4
|
8.3
|
3.9
|
2.2
|
1.3
|
26.0
|
45.5
|
|
EVE
|
84.4
|
66.0
|
42.6
|
29.0
|
20.7
|
15.4
|
4.9
|
2.2
|
1.1
|
0.6
|
19.4
|
34.8
|
|
Independent Weibull curves
|
NIVO
|
90.0
|
76.5
|
53.9
|
36.6
|
24.1
|
15.6
|
1.4
|
0.1
|
< 0.01
|
< 0.001
|
26.3
|
34.0
|
|
EVE
|
84.3
|
67.6
|
43.9
|
28.0
|
17.6
|
11.0
|
1.0
|
0.1
|
< 0.01
|
< 0.001
|
20.4
|
28.3
|
|
Dependent log-logistic curve
|
NIVO
|
89.7
|
74.8
|
53.0
|
39.0
|
29.9
|
23.8
|
10.6
|
6.3
|
4.3
|
2.9
|
26.0
|
50.9
|
|
EVE
|
85.0
|
65.9
|
42.3
|
29.3
|
21.7
|
16.9
|
7.2
|
4.2
|
2.8
|
1.9
|
19.1
|
39.5
|
|
CheckMate 025
|
NIVO
|
89.2
|
76.0
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
25.0
|
–
|
|
EVE
|
81.2
|
66.7
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
19.55
|
–
|
|
CA209-003
|
NIVO
|
82.4
|
70.6
|
48.1
|
41.2
|
37.8
|
34.3
|
–
|
–
|
–
|
–
|
22.4a
|
–
|
|
EVE
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
- The median OS for 1 mg/kg dosing group was 29.3 months; for 10 mg/kg dosing group, the median OS was 18.8 months
- EVE, everolimus; NIVO, nivolumab; OS, overall survival
- aBoth 1 and 10 mg/kg
